SCHEMBL4717435

SCHEMBL4717435

O=c1[nH]ncc2cccc([N+](=O)[O-])c12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 5/20 0.64
MAPT P10636 5/20 0.64
TDP1 Q9NUW8 4/20 0.64
KDM4E B2RXH2 4/20 0.64
HSD17B10 Q99714 3/20 0.64
CYP3A4 P08684 3/20 0.64
MEN1 O00255 3/20 0.64
KMT2A Q03164 3/20 0.64
HPGD P15428 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
CYP1A2 P05177 2/20 0.64
TSHR P16473 2/20 0.64
CYP2C19 P33261 2/20 0.64
NOS2 P35228 2/20 0.64
BLM P54132 2/20 0.64
THRB P10828 1/20 0.64
APEX1 P27695 1/20 0.64
NOS3 P29474 1/20 0.64
RECQL P46063 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
7-Nitroindazole SCHEMBL216995 0.78 NOS1 (1.00) NOS1MAPTTDP1KDM4EHSD17B10
7-Nitroindazole SCHEMBL4297993 0.77 NOS1 (0.97) NOS1MAPTTDP1KDM4EHSD17B10
7-Nitroindazole SCHEMBL4297994 0.77 NOS1 (0.97) NOS1MAPTTDP1KDM4EHSD17B10
SCHEMBL31690218 0.75 NOS1 (0.66) NOS1MAPTTDP1KDM4EHSD17B10
SCHEMBL331389 0.75 NOS1 (0.66) NOS1MAPTTDP1KDM4EHSD17B10
Indazole SCHEMBL27970405 0.73 IDO1 (0.66) NOS1MAPTTDP1KDM4EHSD17B10
SCHEMBL7423121 0.73 ALDH1A1 (0.58) NOS1MAPTTDP1KDM4EHSD17B10
SCHEMBL10595306 0.73 MAPT (0.61) NOS1MAPTTDP1KDM4EHSD17B10
SCHEMBL1009329 0.73 HSD17B10 (0.52) NOS1MAPTTDP1KDM4EHSD17B10
SCHEMBL14911424 0.73 NOS1 (0.56) NOS1TDP1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260035354-A1 PIPERIDINEDIONE DERIVATIVES INNOCURE THERAPEUTICS, INC. (KR) 2026-02-05 US disclosed
EP-4640686-A1 DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Innocure Therapeutics, Inc. (KR) 2025-10-29 EP disclosed
EP-4624466-A1 DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Innocure Therapeutics, Inc. (KR) 2025-10-01 EP disclosed
EP-4624472-A1 DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Innocure Therapeutics, Inc. (KR) 2025-10-01 EP disclosed
US-12384756-B2 Piperidinedione derivatives INNOCURE THERAPEUTICS, INC. (KR) 2025-08-12 US disclosed
WO-2024112122-A1 DEGRADER FOR DEGRADING BRD PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME 주식회사 이노큐어테라퓨틱스 2024-05-30 WO disclosed
WO-2024112119-A1 DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 이노큐어테라퓨틱스 2024-05-30 WO disclosed
WO-2024112120-A1 DEGRADER INCLUDING NOVEL C-MET PROTEIN LIGAND AND PHARMACEUTICAL COMPOSITION INCLUDING SAME 주식회사 이노큐어테라퓨틱스 2024-05-30 WO disclosed
US-20230295105-A1 PIPERIDINEDIONE DERIVATIVES INNOCURE THERAPEUTICS, INC. (KR) 2023-09-21 US disclosed
US-20230295105-A1 PIPERIDINEDIONE DERIVATIVES INNOCURE THERAPEUTICS, INC. (KR) 2023-09-21 US disclosed
CN-116323619-A Piperidinedione derivatives 因诺库尔治疗公司 2023-06-23 CN disclosed
EP-4116298-A1 PIPERIDINEDIONE DERIVATIVE Innocure Therapeutics, Inc. (KR) 2023-01-11 EP disclosed
EP-1664023-B1 SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2008-08-13 EP disclosed
US-7390820-B2 Substituted quinolinone derivatives and methods of use AMGEN INC. (US) 2008-06-24 US disclosed
EP-1664023-A1 SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE AMGEN INC. (US) 2006-06-07 EP disclosed
WO-2005021533-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2005-03-10 WO disclosed
US-20050049253-A1 Substituted quinolinone derivatives and methods of use AMGEN INC. 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035354-A1 PIPERIDINEDIONE DERIVATIVES CRBN, PSMC1, PSME3 NOS1 1343/4885MAPT 4275/4885TDP1 4369/4885
US-20050049253-A1 Substituted quinolinone derivatives and methods of use NQO1, NQO2, UGT1A1 NOS1 214/4885MAPT 3937/4885TDP1 1244/4885
US-20230295105-A1 PIPERIDINEDIONE DERIVATIVES CRBN, CUL1, PSMB10 NOS1 3247/4885MAPT 2906/4885TDP1 4149/4885
US-12384756-B2 Piperidinedione derivatives CRBN, CUL1, PSMB10 NOS1 3247/4885MAPT 2906/4885TDP1 4149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.